EDIT - Editas Medicine Inc

Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.

52W High

$4.12

52W Low

$0.91

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

2.16

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.36

EV/Revenue (<3 favorable)

2.33

P/S (TTM) (<3 favorable)

6.38

P/B (<3 favorable)

12.93

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

0.30%

Institutions (25–75% balanced)

49.13%

Shares Outstanding

89,920,000

Float

89,584,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

38,901,000

Gross Profit (TTM)

-100,123,000

EPS (TTM)

-2.84

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-7.12%

ROE (TTM) (>15% strong)

-1.89%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

5.97

Momentum

Bearish momentum

Value

0.0063

0.0038

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025